clinical trial · NCT05678205
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Breast CancerGastric CancerGastroesophageal Junction AdenocarcinomaAB-201CyclophosphamideFludarabine
brief summary
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases. The primary objective of Phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors. The primary objective of Phase 2 is to evaluate the efficacy of AB-201. Subjects will receive up to 3 doses of AB-201, followed by scheduled assessments of overall health and tumor response.
started
Aug 1, 2023
primary completion
Apr 1, 2027
completion
Apr 1, 2027
last updated
Jul 30, 2025
official title
A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol